Modeling glioblastoma complexity with organoids for personalized treatments
KD Pawlowski, JT Duffy, MV Babak… - Trends in molecular …, 2023 - cell.com
Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of
maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that …
maximal surgical resection, radiation, and temozolomide (TMZ) therapy. One aspect that …
Organoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
RM Ramamurthy, A Atala, CD Porada… - Frontiers in …, 2022 - frontiersin.org
The FDA has predicted that at least 10-20 gene therapy products will be approved by 2025.
The surge in the development of such therapies can be attributed to the advent of safe and …
The surge in the development of such therapies can be attributed to the advent of safe and …
[HTML][HTML] Sensorization of microfluidic brain-on-a-chip devices: Towards a new generation of integrated drug screening systems
Abstract Brain-on-a-chip (BoC) devices show typical characteristics of brain complexity,
including the presence of different cell types, separation in different compartments, tissue …
including the presence of different cell types, separation in different compartments, tissue …
Microphysiological Blood‐Brain Barrier Systems for Disease Modeling and Drug Development
AR Mulay, J Hwang, DH Kim - Advanced Healthcare Materials, 2024 - Wiley Online Library
The blood‐brain barrier (BBB) is a highly controlled microenvironment that regulates the
interactions between cerebral blood and brain tissue. Due to its selectivity, many …
interactions between cerebral blood and brain tissue. Due to its selectivity, many …
Advanced Tissue Technologies of Blood-Brain Barrier Organoids as High Throughput Toxicity Readouts in Drug Development
L Bell, C Simonneau, C Zanini, E Kassianidou… - bioRxiv, 2024 - biorxiv.org
Recent advancements in engineering Complex in vitro models (CIVMs) such as Blood-brain
barrier (BBB) organoids offer promising platforms for preclinical drug testing. However, their …
barrier (BBB) organoids offer promising platforms for preclinical drug testing. However, their …